Skip to main content
MyPeptideMatch logoMyPeptideMatch
Reviewed by MyPeptideMatch Editorial TeamLast reviewed February 2026Updated February 2026

Mazdutide Dosing Protocol: 10 mg Vial — Full Titration & Maintenance Guide

Complete mazdutide titration from 3 mg to 9 mg maintenance using the 10 mg compounded vial, covering the full GLORY Phase 3 dose range.

Quickstart highlights

Mazdutide (IBI362) simultaneously activates GLP-1 receptors (insulin secretion, glucagon suppression, appetite reduction) and glucagon receptors (hepatic fat oxidation, thermogenesis, glycogenolysis).

  • Concentration: 5 mg/mL (10 mg vial + 2 mL bacteriostatic water).
  • At 5 mg/mL: 3 mg = 60 units (0.6 mL), 6 mg = 120 units (1.2 mL), 9 mg = 180 units (1.8 mL).
  • GLORY-1 Phase 3: 6 mg once weekly achieved 14.5% body weight reduction at 36 weeks.
  • Use a 3 mL syringe for the 6 mg and 9 mg doses — volumes exceed 1 mL.
  • One 10 mg vial provides ~1.67 doses at 6 mg/week; plan weekly reconstitution at this dose level.

Dosing table

For educational reference only. Your prescribing provider may adjust doses based on your clinical profile and response.

WeekDose (µg)UnitsFrequencyNotes
1-8300060Once weekly3 mg — 60 units; 10 mg vial provides ~3.3 doses at this level
9-166000120Once weekly6 mg maintenance — 120 units (1.2 mL); use 3 mL syringe; vial provides ~1.67 doses
17+9000180Once weekly9 mg high-dose — 180 units (1.8 mL); GLORY Phase 3 high-dose arm; approximately 1.11 doses per vial

Reconstitution steps

  1. Draw 2 mL bacteriostatic water; inject slowly down the vial wall.
  2. Swirl gently until fully dissolved; do not shake.
  3. Final concentration: 5 mg/mL (10 mg / 2 mL). For 6 mg dose: draw 1.2 mL; for 9 mg: draw 1.8 mL — use 3 mL syringe.
  4. Label with date; refrigerate at 2–8 °C. Use within 28 days.

Supplies needed

8-week plan

  • 1 vial
  • 8 syringes
  • 2 mL bac water
  • 8 alcohol swabs

16-week plan

  • 4 vials
  • 16 syringes
  • 8 mL bac water
  • 16 alcohol swabs

24-week plan

  • 6 vials
  • 24 syringes
  • 12 mL bac water
  • 24 alcohol swabs
Need clinics? See vetted providers →

Protocol overview & cycle notes

Provide full-cycle mazdutide coverage from 3 mg initiation through 6–9 mg maintenance using the 10 mg vial, supporting weight loss and glycemic control via dual GLP-1/glucagon agonism per the GLORY Phase 3 protocol.

Cycle length: 24 weeks on.

Off-cycle: 8–12 weeks off; monitor HbA1c and body weight.

Storage & handling

Lyophilized: store below 25 °C. Reconstituted at 5 mg/mL: refrigerate 2–8 °C; use within 28 days. For the 6 mg dose (1.2 mL) and 9 mg dose (1.8 mL), always use a 3 mL syringe.

Injection & tracking tips

  • Use a 3 mL syringe for doses above 5 mg — the 6 mg dose requires 1.2 mL, exceeding a standard 1 mL U-100 syringe.
  • Rotate injection sites weekly.
  • Hydration is important at higher doses — maintain ≥2 L water daily, especially at 9 mg where glucagon effects increase urinary output.

Tracking

Logging helps you and your provider spot patterns and adjust dose or timing.

  • Record body weight weekly; GLORY-1 Phase 3 showed 14.5% weight reduction at 6 mg over 36 weeks.
  • Track fasting blood glucose and HbA1c every 8 weeks.
  • Monitor ALT/AST monthly at doses ≥6 mg; the glucagon component increases hepatic enzyme activity transiently.
Log your cycle in the calculator →

How this works & references

Mazdutide (IBI362) simultaneously activates GLP-1 receptors (insulin secretion, glucagon suppression, appetite reduction) and glucagon receptors (hepatic fat oxidation, thermogenesis, glycogenolysis). The GLORY-1 Phase 3 trial (NCT05564910) demonstrated 14.5% body weight reduction at 6 mg over 36 weeks. The 9 mg arm data are pending final Phase 3 analysis. Chinese regulatory approval for T2DM obtained 2023; US FDA submission is in progress.

Frequently asked questions

How many 10 mg vials do I need for a 16-week titration?
Approximately 4 vials: weeks 1–8 at 3 mg use ~2.4 vials (each vial yields ~3.3 doses); weeks 9–16 at 6 mg use ~4.8 vials (each vial yields ~1.67 doses). Round up to 4 vials total for the titration phase.
Can mazdutide treat fatty liver disease?
Emerging Phase 3 data from China suggest significant hepatic fat reduction. The glucagon receptor component directly stimulates hepatic β-oxidation, similar to survodutide and retatrutide. Formal MASH/NASH trials are under development.
Is 9 mg the maximum dose?
Based on GLORY Phase 3 protocols, 6 mg is the primary maintenance dose. A 9 mg high-dose arm is also being evaluated. Doses above 9 mg have not been formally studied in Phase 3.
How does mazdutide perform compared to semaglutide for T2DM?
Mazdutide was non-inferior to semaglutide 1 mg for HbA1c reduction in Chinese T2DM populations and showed superior weight loss. Direct comparison to higher semaglutide doses (2.4 mg) for obesity is not yet available.
What is the off-cycle protocol?
A structured 8–12 week off-cycle is recommended. Expect partial weight regain during the off-cycle — typically 30–50% of lost weight over 6 months. Discuss maintenance-dose cycling or dose de-escalation with your prescribing clinician.

Related protocols

This content is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any peptide therapy. Dosing and protocols may vary by formulation and prescriber.